News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Celgene (JOBS) Investors Struggle with Confusing Data
December 9, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Celgene Corp (CELG.O) investors were struggling on Tuesday to sort through confusing results from a key trial of the company's cancer drug Revlimid.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Postmarket research
MORE ON THIS TOPIC
Neuroscience
Rapport Jumps 180% on ‘Best Case’ Mid-Stage Data for Epilepsy Pill
September 8, 2025
·
2 min read
·
Heather McKenzie
Lung cancer
Summit’s Keytruda Challenger Hits Cross-Country Consistency Problems, Raising US Approval Questions
September 8, 2025
·
2 min read
·
Tristan Manalac
Lung cancer
Merck, Daiichi Sankyo Stage Lung Cancer Rally With ‘Strong’ Pivotal Data for I-Dxd
September 8, 2025
·
2 min read
·
Tristan Manalac
Psychedelics
With Lykos MDMA Rejection Letter Out, MAPS Founder Decries ‘Change of the Goal Posts’
September 5, 2025
·
3 min read
·
Dan Samorodnitsky
